Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Status:
Withdrawn
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dovitinib lactate works in treating patients with
pancreatic neuroendocrine tumors. Dovitinib lactate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.